✦ LIBER ✦

Lung-derived growth factor that stimulates the growth of lung-metastasizing tumor cells: Identification as transferrin

✍ Scribed by Philip G. Cavanaugh; Garth L. Nicolson

Publisher: John Wiley and Sons
Year: 1991
Tongue: English
Weight: 1023 KB
Volume: 47
Category: Article
ISSN: 0730-2312
DOI: 10.1002/jcb.240470312

No coin nor oath required. For personal study only.

✦ Synopsis

We have previously shown that culture medium conditioned by lung fragments contains mitogenic activity for lung-metastasizing tumor cells but not for their non-metastatic counterparts. The growth-promoting component from media conditioned by rat and porcine lungs has been purified and partially characterized as a M, = 66,000 (unreduced) or M, = 72,000 (reduced) glycoprotein [

📜 SIMILAR VOLUMES

Purification and characterization of a M

Purification and characterization of a Mr ∼66,000 lung-derived (paracrine) growth factor that preferentially stimulates the in vitro proliferation of lung-metastasizing tumor cells

✍ Philip G. Cavanaugh; Garth L. Nicolson 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 967 KB

In medium containing low concentrations of serum, rat 13762NF mammary adenocarcinoma cell lines and clones (MTPa and MTC; isolated from the locally growing tumor) of low metastatic potential to lung did not exhibit a growth response to lung-conditioned medium, whereas a highly metastatic cell clone

Mechanism of blood-borne metastases. I.

Mechanism of blood-borne metastases. I. Some factors affecting lodgment and growth of tumor cells in the lungs

✍ Akihiko Koike 📂 Article 📅 1964 🏛 John Wiley and Sons 🌐 English ⚖ 945 KB

This investigation was aided by a grant (P-312) from ,the American Cancer Society, Inc. The author is grateful to Dr. George E. Moore for his advice throughout the study and for his criticism in the preparation of the manuscript.

Stromal cell-derived factor-1 stimulates

Stromal cell-derived factor-1 stimulates vasculogenesis and enhances Ewing's sarcoma tumor growth in the absence of vascular endothelial growth factor

✍ Krishna Reddy; Zhichao Zhou; Shu-Fang Jia; Tim H. Lee; Jaime Morales-Arias; Ying 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 292 KB 👁 1 views

## Abstract Stromal cell‐derived Factor‐1α (SDF‐1α) stimulates the migration of bone marrow (BM) cells, similar to vascular endothelial growth factor (VEGF). We previously demonstrated that inhibition of VEGF~165~ by small interfering RNA inhibited Ewing's sarcoma tumor growth, tumor vessel formati

Evaluation of denaturing high-performanc

Evaluation of denaturing high-performance liquid chromatography as a rapid detection method for identification of epidermal growth factor receptor mutations in nonsmall-cell lung cancer

✍ Victor Cohen; Jason S. Agulnik; Jonathan Jarry; Gerald Batist; David Small; Harv 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 286 KB 👁 2 views

## Abstract ## BACKGROUND. Somatic mutations of the epidermal growth factor receptor (__EGFR__) gene in nonsmall‐cell lung cancer (NSCLC) may predict responsiveness to tyrosine kinase inhibitors. These mutations are commonly identified using DNA sequencing methods. Although considered the gold sta

Bombesin/gastrin-releasing peptide antag

Bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II inhibit tumor growth and decrease the levels and mRNA expression of epidermal growth factor receptors in H-69 small cell lung carcinoma

✍ Miklós Koppán; Gábor Halmos; José M. Arencibia; Najib Lamharzi; Andrew V. Schall 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 134 KB 👁 1 views

## BACKGROUND. Antagonists of bombesin/gastrin-releasing peptide (BN/GRP) have been developed to block the autocrine stimulatory effect of BN/GRP on tumors such as small cell lung carcinoma (SCLC). Although several studies have addressed the intracellular events that follow the formation of the re

Response to dual blockade of epidermal g

Response to dual blockade of epidermal growth factor receptor (EGFR) and cycloxygenase-2 in nonsmall cell lung cancer may be dependent on the EGFR mutational status of the tumor

✍ Shirish M. Gadgeel; Shadan Ali; Philip A. Philip; Fakhara Ahmed; Antoinette Wozn 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 332 KB 👁 1 views

## Abstract ## BACKGROUND. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) have demonstrated clinical benefit in patients with nonsmall cell lung cancer (NSCLC), particularly those with tumors that have EGFR‐TK domain mutations. Moreover, the EGFR and cyclooxygenase (COX)‐2